Trial Profile
Phase II Randomized Trial of Radiotherapy With Concurrent and Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy in Patients With Advanced/Intermediate-Risk p16+ Head and Neck Squamous Cell Carcinoma (KEYCHAIN)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 May 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Cisplatin
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Nasopharyngeal cancer; Oropharyngeal cancer; Pharyngeal disorders; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms KEYCHAIN
- 01 May 2023 Planned End Date changed from 1 Jun 2024 to 1 Jun 2025.
- 01 May 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Aug 2024.
- 07 Oct 2021 Planned primary completion date changed from 1 Apr 2021 to 1 Apr 2023.